June 2021 Rx Product News

Cabotegravir and Rilpivirine Combination (Cabenuva)

Manufactured by ViiV Healthcare

Cabotegravir extended-release injectable suspension and rilpivirine extended- release injectable suspension is the only once-monthly complete treatment for HIV-1. It is available through AllianceRx Walgreens Prime for adults who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to either of the drugs’ components. The combination treatment provides an alternative for patients who previously relied on a daily oral treatment regimen.

For more information: cabenuva.com

Spinosad Topical Suspension, 0.9% (Natroba)

Manufactured by ParaPRO

The FDA has recently approved spinosad topical suspension, 0.9% for scabies infestations in both adult and pediatric patients 4 years and older. The drug was previously approved for the topical treatment of head lice in January 2011. This new approval represents the first important pharmacological advancement in scabies treatments in decades, according to a statement from William Culpepper III, president of ParaPRO. According to clinical trial results, spinosad is highly effective and well tolerated following a single application, and it could represent a new standard of care for scabies treatment.

For more information: parapro.com

Drospirenone and Estetrol (Nextstellis)

Manufactured by Mayne Pharma

FDA officials have approved a new combined oral contraceptive tablet of 3 mg drospirenone and 14.2 mg estetrol. It is the first and only contraceptive pill containing estetrol, making it the first new estrogen product to be introduced in the United States in more than 50 years. In phase 3 clinical trials conducted in 3725 women, the contraceptive was found to be effective and safe and demonstrated excellent bleeding and cycle control, safety, and tolerability.

For more information: maynepharma.com

Omalizumab (Xolair)

Manufactured by Genentech

Patients with certain allergic and inflammatory conditions have increased flexibility in their treatment regimens with the recent FDA approval of omalizumab prefilled syringe for self-injection across all approved indications. Omalizumab is the only FDA-approved antibody that targets and blocks IgE, downregulating high-affinity IgE receptors and limiting mast cell degranulation to treat moderate to severe persistent allergic asthma, chronic urticaria, and nasal polyps. Patients starting therapy with omalizumab will begin with administration by a health care provider, who will then determine whether they are eligible for prefilled syringe self-injections.

For more information: gene.com